At a glance
ClinicalIndex Comparison Record- ✓Pathologically confirmed soft tissue sarcoma or bony sarcoma
- ✓Tumor tissue available for EGFR assessment by immunohistochemistry (IHC)
- ✓Zubrod performance status 0–2
- ✓Age 16 years or older
- ✕Acute hepatitis or known HIV
- ✕Active or uncontrolled infection
- ✕Significant uncontrolled cardiac disease (uncontrolled hypertension, unstable angina, recent MI within 6 months, uncontrolled CHF, cardiomyopathy with decreased EF)
- ✕Prior therapy targeting the EGFR pathway
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas
In Brief
A Phase 2 clinical trial evaluating Cetuximab for Sarcoma. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The purpose of this study is to explore how this cancer is affected by a new medication, cetuximab. Cetuximab is directed towards a protein called EGFR (epidermal growth factor receptor), that is found in some types of cancer. Studies have shown that this drug can be beneficial in patients with colon cancer and has been approved by the US Food and Drug Administration (FDA) for this purpose. The researchers are conducting a study to see if it is beneficial in patients with sarcoma.
Study Details
Timeline
Interventions
The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min